Altre lingue Arbutus Biopharma Corporation

Azioni

ABUS

CA03879J1003

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 24/04/2024			Variaz. 5gg	Var. 1 gen.
2,75 ^USD	+0,36%		-1,08%	+10,00%

05/04	Arbutus Biopharma ottiene un'ordinanza favorevole del Tribunale nella causa sul brevetto Moderna	MT
04/04	Moderna subisce una battuta d'arresto nella causa intentata da Arbutus	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update	18/04
Arbutus Biopharma : Corporate Presentation - April 2024	15/04
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	05/04
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna	04/04
Moderna Suffers Setback in Lawsuit by Arbutus	04/04
Moderna shares fall after judge sides with Arbutus in patent fight	03/04
Arbutus to Participate in Two Upcoming Investor Conferences	08/03
Arbutus to Participate in Two Upcoming Investor Conferences	08/03
Arbutus Biopharma Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update	01/03
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update	29/02
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update	29/02
Arbutus Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update	15/02
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update	08/01
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update	08/01
Arbutus Biopharma, Inc. Announces Clinical Development Milestones to Advance Its HBV Pipeline	08/01
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD	09/11
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®	09/11
Arbutus to Present at Jefferies London Healthcare Conference	08/11
Arbutus to Present at Jefferies London Healthcare Conference	08/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Arbutus Biopharma Corporation

Azioni

ABUS

CA03879J1003

Altre lingue

Filtri